TY - JOUR T1 - Late-breaking abstract: Clinical characteristics in French COPD patients: First results of Palomb cohort JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P4948 AU - Chantal Raherison AU - Emilie Berteaud AU - Alain Bernady AU - Laurent Falque AU - Julien Casteigt AU - Cecilia Nocent-Eijnaini AU - Frederic Le Guillou AU - Laurent Nguyen AU - Jean Moinard AU - Christophe Roy AU - François Pellet Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P4948.abstract N2 - COPD became now a major cause of morbidity and mortality around the world. However, in France epidemiological data regarding COPD management in real life are scarce.The objective of our study was to describe COPD management by pulmonologists in south-West of France in an observational cohort.45 pulmonologists included n=498 patients with COPD using a web-site questionnaire. Diagnosis of COPD was made using spirometry VEMS/CVF<70% post bronchodilator. 67% of patients were men, 66 years old. 35% were still active-smokers and 59% ex-smokers. Respiratory symptoms began for 3% of patients between 30-39 yrs old, 12% between 40-49 yrs old, and 22% between 50-59 yrs old, and 19, 7% between 60-69 yrs old.83% of the patients were referred to the pulmonologist by the general practitioner. 58% had chronic cough, and 45% had chronic sputum. Frequency of dypnea (Sadoul scale) was: 13% level 0, 26% level I, 26% level II, 24% level III, and 6% level IV. Regarding frequency of exacerbations, 64% of the patients reported one to three exacerbation during the past 12 months, 6% more than three exacerbations and 30% no exacerbation. The most frequent co morbidities were: hypertension (41%), dyslipidemia (28%) and ischemic cardiopathy (24%). Regarding GOLD classification, 19% was GOLD I, 56% GOLD II, 21% GOLD III, and 2% GOLD IV. 49% of the patients had a probability of mortality at four years around 15% (BOD score). Our study show clinical characteristics of COPD patients at baseline. Follow-up of these COPD patients will provide interesting information regarding clinical phenotypes and management in real-life.Funding: Foundation of Bordeaux University, Novartis Pharma, Isis Medical. ER -